Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Trial record 1 of 1987 for:    Open Studies | "Hematologic Diseases"
Previous Study | Return to List | Next Study

Identification and Analysis of Immunomodulatory Molecules in Patients With Hematologic Disorders and Healthy Volunteers

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2013 by The University of Texas Health Science Center at San Antonio
Sponsor:
Collaborator:
Information provided by (Responsible Party):
The University of Texas Health Science Center at San Antonio
ClinicalTrials.gov Identifier:
NCT00223483
First received: September 13, 2005
Last updated: April 2, 2013
Last verified: April 2013
  Purpose

This research study goal is to analyze the plasma and the cells that make up part of the immune system. We want to learn how the plasma and cells work. These may influence why one person will develop an infection and another will not, or why one person develops severe symptoms of a disease while others remain without symptoms.


Condition Intervention
Hematologic Diseases
Healthy Volunteers
Genetic: Isolation of genomic DNA

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Identification and Analysis of Immunomodulatory Molecules From Leukocytes in Patients With Hematologic Disorders and Healthy Volunteers

Resource links provided by NLM:


Further study details as provided by The University of Texas Health Science Center at San Antonio:

Primary Outcome Measures:
  • Repository collection of plasma and serum for future analysis. [ Time Frame: 12 years ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

Whole blood, serum, white cells


Estimated Enrollment: 1000
Study Start Date: March 2005
Estimated Study Completion Date: March 2015
Estimated Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)
Intervention Details:
    Genetic: Isolation of genomic DNA
    One time blood draw
Detailed Description:

This research study goal is to analyze the plasma and the cells that make up part of the immune system. These cells, called white cells or leukocytes, are present in blood. We want to learn how these cells work to prevent infection and how they respond after an infection occurs. We also want to study certain molecules present on the plasma, on or in these cells, and the genetic material that allows these molecules to be made. These molecules may influence why one person will develop an infection and another will not, or why one person develops severe symptoms of a disease while others remain without symptoms. This study may increase our understanding of a variety of diseases including infections such as HIV, allergic diseases such as asthma, joint diseases such as rheumatoid arthritis, certain cancers, and the rejection process that sometimes occurs after transplantation of an organ.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Primary care clinic and community samples

Criteria

Inclusion Criteria:

  • Must be able to give blood
  • Must be able to give informed consent
  • Signed, written informed consent

Exclusion Criteria:

  • Individuals with a history severe anemia, inadequate venous access, severe blood or coagulation disorders.
  • Pregnant women are excluded because it is a unique immunotolerant state and will alter the profile of immunomodulatory molecules.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00223483

Contacts
Contact: Juan J Toro, MD 210-617-5300 ext 16777 juantoro2@va.gov

Locations
United States, Texas
Department of Veterans Affairs, South Texas Veterans Health Care System, Audie L. Murphy Memorial Veterans Hospital Division Recruiting
San Antonio, Texas, United States, 78229
Contact: Juan J Toro, MD    210-617-5300 ext 16777    juantoro2@va.gov   
Principal Investigator: Juan J Toro, MD         
The University of Texas Health Science Center at San Antonio Recruiting
San Antonio, Texas, United States, 78229
Contact: Juan J Toro, MD    210-617-5300 ext 16777    juantoro2@va.gov   
Principal Investigator: Juan J Toro, MD         
Sponsors and Collaborators
The University of Texas Health Science Center at San Antonio
Investigators
Study Director: Cesar O Freytes, MD The University of Texas Health Science Center at San Antonio
  More Information

No publications provided

Responsible Party: The University of Texas Health Science Center at San Antonio
ClinicalTrials.gov Identifier: NCT00223483     History of Changes
Other Study ID Numbers: HSC20040268H
Study First Received: September 13, 2005
Last Updated: April 2, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by The University of Texas Health Science Center at San Antonio:
Hematologic Diseases
Genomics
Cytokines
Chemokines
Receptors

Additional relevant MeSH terms:
Hematologic Diseases

ClinicalTrials.gov processed this record on November 20, 2014